PVCT (PVCT) CEO converts 8% note and Series D-1 preferred into common stock

Rhea-AI Filing Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported non‑market transactions converting debt and preferred equity into common stock. An 8% unsecured convertible promissory note converted into 49,067 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share. Those 49,067 Series D-1 shares were then converted into 490,670 shares of common stock, reflecting the 10:1 conversion ratio. Following these conversions, Pershing directly holds 2,710,054 shares of common stock. The Series D-1 Preferred Stock is also described as automatically converting into common stock on December 31, 2028 unless converted earlier under its terms.

Insider Trade Summary

49,067 shares exercised/converted

Mixed 2 txns

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Exercise	8% Unsecured Convertible Promissory Note	0	$0.00	--
Exercise	Series D-1 Convertible Preferred Stock	49,067	$0.00	--

Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 shares (Direct); Series D-1 Convertible Preferred Stock — 2,710,054 shares (Direct)

Footnotes (1)

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing. On March 20, 2026, the 2025 Note was converted into 49,067 shares of Series D-1 Preferred Stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TENNESSEE 37929

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	03/20/2026		M			$130,000	03/20/2025	03/20/2026	Series D-1 Convertible Preferred Stock(3)(4)	49,067	$0	$1,185,000	D
Series D-1 Convertible Preferred Stock	(1)	03/20/2026		M		49,067		03/20/2026	(2)	Common Stock	490,670	$0	2,710,054	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.

4. On March 20, 2026, the 2025 Note was converted into 49,067 shares of Series D-1 Preferred Stock.

	/s/ Edward Pershing	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did PVCT CEO Edward Pershing report on this Form 4?

Edward Pershing reported two non-market derivative conversions. An 8% unsecured convertible note converted into 49,067 Series D-1 preferred shares, which then converted into 490,670 common shares. These actions reflect restructuring of his holdings rather than open-market buying or selling.

How many Provectus Biopharmaceuticals (PVCT) common shares did Pershing acquire through these conversions?

Pershing acquired 490,670 shares of Provectus common stock through conversion of 49,067 Series D-1 Convertible Preferred shares. Each preferred share converts into 10 common shares, as disclosed, turning the preferred position into a larger direct common stock holding.

What is the conversion price of the 8% note in the PVCT Form 4 filing?

The 8% unsecured convertible promissory note converted into Series D-1 Preferred Stock at $2.862 per share. This price governed how much preferred equity Pershing received when the note’s outstanding principal and interest automatically converted into 49,067 Series D-1 preferred shares.

How many Provectus (PVCT) common shares does Edward Pershing hold after the reported transactions?

After the reported conversions, Pershing directly holds 2,710,054 Provectus common shares. This figure includes the 490,670 new common shares received from converting 49,067 Series D-1 Preferred shares, giving a clearer picture of his post-transaction equity position.

What are the key terms of PVCT’s Series D-1 Convertible Preferred Stock mentioned in the filing?

Each Series D-1 Preferred share converts into 10 common shares of Provectus. The preferred stock will automatically convert into common stock on December 31, 2028, unless it is converted earlier according to the Series D-1 Certificate of Designation terms.

Did Edward Pershing buy or sell PVCT shares on the open market in this Form 4?

The Form 4 shows no open-market purchases or sales. Instead, it reports derivative exercises and conversions: an 8% convertible note into Series D-1 Preferred, and those preferred shares into common stock, changing the form of Pershing’s holdings without market trades.